St Jude Medical Inc: (NYSE: STJ)

$45.70

-1.08 (-2.31%)

Volume 2,803,481

May 22 04:03 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		45.43 - 47.45
	
		52wk Low - High
		30.25 - 47.45
	
		Previous Close
		46.78
	
		Avg. Volume
		2,368,125
	
		Industry
		MED PRODUCTS
	
		Market Cap
		13.24 B
	
		Div - Yield
		1.00 - 2.14
	
		Beta
		0.85
	
		PE (Forward)
		12.64
	
		Current Year Est.
		3.70
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		177 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/9/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            12.64
                        
                            PEG Ratio
                            1.46
                        
                            Current Year Est.
                            3.70
                        
                            Current Quarter Estimate
                            0.94
                        
                            Most Accurate Estimate
                            0.94
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-17-2013
                        
                            EPS Last Year
                            3.55
                        
                            Expected Earnings Growth
                            8.65%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
St. Jude Medical, Inc. is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation.   
Full STJ Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
STJ Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.94	0.88	3.70	3.94
Number of Estimates	17	17	17	18
Low Estimate	0.93	0.86	3.68	3.76
High Estimate	0.95	0.90	3.73	NA
Year Ago EPS	0.88	0.83	3.48	3.70
EPS Growth	6.82%	6.38%	6.37%	6.48%

More STJ Estimates

Average Earnings Estimates for STJ

EPS Growth for STJ

Industry Analysis

Name	Symbol	Previous Close
ST JUDE MEDICAL	STJ	46.78
CONCEPTUS INC	CPTS	30.98
ATRICURE INC	ATRC	8.99
INVIVO THERAPT	NVIV	2.90
TRANS1 INC	TSON	1.59
ABAXIS INC	ABAX	44.22
ADVAXIS INC	ADXS	0.05
BAXTER INTL	BAX	73.04
BIO-RAD LABS -A	BIO	116.12
BIOLIFE SOL INC	BLFS	0.38

Sector:Medical>> Industry:MED PRODUCTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Medtronic Beats Earnings, Results Stronger

May 22, 2013

CE Mark for STJ's ILUMIEN OPTIS

May 17, 2013

Study for STJ's Latest EnligHTN

May 15, 2013

Good News for STJ's Durata

May 14, 2013

CE Mark for STJ's Ellipse & Assura

May 13, 2013

St. Jude Reiterated at Neutral

May 10, 2013

St. Jude's New Quadra Study

May 07, 2013

Greatbatch 1Q Earnings Beat Ests; Sales Dip

Apr 26, 2013

More STJ Zacks Commentary

Financials

EPS TTM	3.55
Sales	5,503
Net Income	763
Price/Earnings	13.18
Price/Book	3.46
Price/Cash Flow	10.54
Price/Sales	2.43

More STJ Financials

News

St Jude Medical (STJ) Showing Bullish Technicals But Could Fall Through $46.27 Support - Freshbrewedmedia

May 22, 2013

St. Jude Medical receives CE mark approval for new portfolio of ICDs and CRT-Ds - Datamonitor

May 22, 2013

Watch for Continued Gains in Shares of St Jude Medical (STJ) - Financial News Netwfork Online - 52-Week High-Lows

May 22, 2013

St Jude Medical: 52-Week High Recently Eclipsed (STJ) - Financial News Netwfork Online - 52-Week High-Lows

May 21, 2013

St. Jude Medical EnligHTNment Study Highlighted at EuroPCR During Trials That May Change Clinical Practice Session - Businesswire

May 21, 2013

St. Jude Medical to Present at the 38th Annual Deutsche Bank Health Care Conference - Businesswire

May 21, 2013

What`s Behind Medtronic`s 5% Pop? - TheMotleyFool

May 21, 2013

Zynex Ranks the Highest in Terms of Forward Earnings Yield in the Health Care Equipment Industry (ZYXI, STJ, HOLX) - Financial News Network Online - News Corner

May 21, 2013

See All News Stories on STJ

Broker Recommendations

Current ABR	2.12
ABR (Last Week)	2.12
# of recs in ABR	25
Average Target Price	44.68
Industry Rank by ABR	177 out of 265
Rank in Industry	5 out of 73

More STJ Broker Recommendations

Day Low - High	45.43 - 47.45
52wk Low - High	30.25 - 47.45
Previous Close	46.78
Avg. Volume	2,368,125
Industry	MED PRODUCTS
Market Cap	13.24 B
Div - Yield	1.00 - 2.14
Beta	0.85
PE (Forward)	12.64
Current Year Est.	3.70
Quarterly Earnings ESP	0.00%

PE (Forward)	12.64
PEG Ratio	1.46
Current Year Est.	3.70
Current Quarter Estimate	0.94
Most Accurate Estimate	0.94
Earnings ESP	0.00%
Next Earnings Report Date	07-17-2013
EPS Last Year	3.55
Expected Earnings Growth	8.65%

Username: Password:

Remember me [?]

St Jude Medical Inc: (NYSE: STJ)

$45.70

-1.08 (-2.31%)

Volume 2,803,481

May 22 04:03 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED PRODUCTS

Zacks Commentary

Financials

News

Broker Recommendations